ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California.
| Revenue (TTM) | $98.99M |
| Gross Profit (TTM) | $58.81M |
| EBITDA | $-200.93M |
| Operating Margin | -265.20% |
| Return on Equity | -136.40% |
| Return on Assets | -41.10% |
| Revenue/Share (TTM) | $1.00 |
| Book Value | $0.62 |
| Price-to-Book | 13.87 |
| Price-to-Sales (TTM) | 8.13 |
| EV/Revenue | 7.53 |
| EV/EBITDA | -9.88 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 184.50% |
| Shares Outstanding | $99.30M |
| Float | $42.45M |
| % Insiders | 16.21% |
| % Institutions | 95.47% |
Volatility is currently expanding
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company
ARS Pharmaceuticals stock lost more than 23% of its value in a single after-hours session after Neffy® failed to secure any new formulary additions in the July 2026 payer cycle -- a result that contradicted repeated executive coverage projections. NEW YORK, July 6, 2026 /PRNewswire/ -- Shareholders who held ARS Pharmaceuticals (NASDAQ: SPRY) stock watched more than 23% of their investment disappear on June 24, 2026, when the Company disclosed that Neffy® received zero new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle.
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ARS Pharmaceuticals CEO projected CVS Caremark formulary inclusion was expected for the July 1, 2026 commercial formulary cycle -- the July 2026 payer cycle produced zero new formulary additions, and SPRY fell more than 23%. NEW YORK, June 29, 2026 /PRNewswire/ -- Investors in ARS Pharmaceuticals (NASDAQ: SPRY) lost more than 23% of their investment value in after-hours trading on June 24, 2026, after the Company disclosed that Neffy® -- its flagship epinephrine nasal spray -- received zero new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle.
LOS ANGELES--(BUSINESS WIRE)---- $SPRY--SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.
No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion
ARS Pharmaceuticals is now focused on scaling Neffy. This is their needle-free epinephrine spray for severe allergic reactions, and it's also core to my bull case on SPRY. Recently, we've seen SPRY double down on CVS Caremark, Medicaid, retail affordability, and a larger sales force to improve Neffy's access by 2H2026. Neffy is already generating commercial revenue, and the next test for my bull case is whether repeat sales grow as access improves.
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
ARS Pharmaceuticals NASDAQ: SPRY reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for neffy, its needle-free epinephrine treatment for allergic reactions including anaphylaxis.
